期刊文献+

反相HPLC法测定依折麦布片的含量及有关物质 被引量:2

Determination of ezetimibe and its related substances by RE-HPLC
原文传递
导出
摘要 目的:采用反相HPLC法测定依折麦布片的有关物质及含量。方法采用HPLC法,色谱柱为Hypersil BDS (150mm×4.6mm,5μm);流动相为0.05mol/L磷酸二氢钾溶液-乙腈-四氢呋喃(65:25:10)等度洗脱;流速为1.0mL.min^-1;柱温为30℃;检测波长为232nm。结果所采用的分析方法,能较好的分离依折麦布片的有关物质,其线性范围是98.6~295.9μg/ml(r=0.9999),最低检测限0.9ng,平均回收率为100.3%,方法精密度RSD=0.72%(n=9)。结论该方法操作简单,灵敏度高,准确可靠,可用于测定依折麦布片的含量及有关物质。 Objective To establish an RE-HPLC method for the determination of ezetimibe and its related substances in ezetimibe tablets. Methods The analysis was performed on a Cl8 column(150mm×4.6mm, 5μm). The mobile phase consisted of potassium dihydrogen phosphate 0.05mol/L:acetonitrile:tetrahydrof uran=65∶25∶10. The flow rate was 1.0mL?min-1 and the column temperature maintained at 30℃. The detectivewavelength was 232 nm. Results Ezetimibe and its related substances were well-separated by this method, and the linear range of ezetimibe was 98.6~295.9μg/ml, r=0.9999. The average recovery of ezetimibe was 100.3% with the RSD was 0.72% (n=9). Conclusion This method is simple, sensitive and accurate,which can be used for the quality control in ezetimbie tablets.
出处 《首都医药》 2014年第22期99-101,共3页 Capital Medicine
关键词 HPLC 依折麦布 含量测定 有关物质检查 HPLC ezetimibe tablets contentdetermination related substance
  • 相关文献

参考文献6

  • 1Rosenblum SB, Huynh T, Alfonse A, et al. Discovery of 1 -(4-fluorophenyl) -(3R)-[3-(4- florophenyl)-3S- hydroxypropyl]-(4S)- (4-hydroxypropyl)- 2-azetidinone(SCn 58235): a designed, potent, orally active inhibitor of cholesterol absorption[J]. J.Med. Chem, 1998, 47,973.
  • 2杨宏,樊朝美.新型选择性胆固醇吸收抑制剂依泽麦布[J].中国临床药理学杂志,2005,21(4):303-306. 被引量:7
  • 3Davidson MH, Mc Garry T, Bettis 1t, et al. J Am Coll Cardiol 2002, 40(12): 2125-2134.
  • 4Clader J W. The Discovery of Ezetimibe: A View from Outside the 11eceptor [J]. J Med Chem, 2004, 47 (1) : 1-9.
  • 5熊祯,翟所迪,陈凤荣.新型血脂调节药——依折麦布[J].中国新药与临床杂志,2007,26(11):864-868. 被引量:23
  • 6中华人民共和国国家药典委员会.中国药典第二部[S].北京:中国医药科技出版社,2010.附录VD.

二级参考文献40

  • 1刘治军,刘瑶,傅得兴,孙春华.新型胆固醇吸收抑制剂依泽替米贝的不良反应[J].药物不良反应杂志,2005,7(6):466-468. 被引量:1
  • 2Assmann G, Cullen P, Schulte H. The Munster heart study (PROCAM) :Results of follow - up at 8 years[J]. Eur Heart J, 1998;19( Suppl. ): S2 - S11.
  • 3Straka RJ, Taheri R, Cooper SL, et al. Assessment of hypercholesterolemia control in a managed care organization [ J ]. Pharmacotherapy,2001 ;21:818 -827.
  • 4Sueta CA, Chowdhury M, Boccuzzi SJ, et al. Analysis of the degree of undertrearment of hyperlipidemia and congestive heart failure secondary to coronary artery disease[ J]. Am J Cardiol, 1999 ;83:1303 - 1307.
  • 5Zetia (ezetimibe) Kenilworth, NJ: Schering Corporation. Package insert [J/OL]. http ://www. vapbm. org,2004 -03 - 01.
  • 6Sudhop T, Lujohann D, Kodal A, et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans [ J ]. Circulation, 2002; 106:1943 - 1948.
  • 7Dujone CA, Ettinger MP, McNeer JF, et al. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia[ J ]. Am J Cardiol, 2002;90:1092 - 1097.
  • 8Knopp RH, Gitter H, Truitt T, et al. Ezetimibe reduces low - density lipoprotein cholesterol: Results of a phase Ⅲ, randomized, doubleblind, place - controlled trial [ J ]. Atherosclerosis, 2001; 2 ( Suppl ):S38.
  • 9Bays HE, Moore PB, Drehobl MA, et al. Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: Pooled analysis of two phase Ⅱ studies[J]. Clin Ther, 2001 ;23:1209 - 1230.
  • 10Davidson M, McGarry T, Bettis R, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia [ J ]. J Am Coll Cardiol, 2002 ;40:2125 - 2134.

共引文献28

同被引文献16

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部